![]() |
![]() |
[ Ana Sayfa | Editörler | Danışma Kurulu | Dergi Hakkında | İçindekiler | Arşiv | Yayın Arama | Yazarlara Bilgi | E-Posta ] |
Fırat Tıp Dergisi |
2019, Cilt 24, Sayı 2, Sayfa(lar) 089-096 |
[ Turkish ] [ Tam Metin ] [ PDF ] |
The Rates of Coexistence Metastases in Patients with Advanced Prostate Cancer in 68Ga-PSMA PET/CT: A Retrospective Analysis |
Halil KÖMEK1, Tansel Ansal BALCI2 |
1Sağlık Bilimleri Üniversitesi Diyarbakır Gazi Yaşargil Eğitim ve Araştırma Hastanesi, Nükleer Tıp Kliniği, Diyarbakır, Türkiye 2Fırat Üniversitesi Tıp Fakültesi, Nükleer Tıp Anabilim Dalı, Elazığ, Türkiye |
Objective: To determine the rate of metastasis and coexistence metastases in patients with advanced prostate cancer in gallium 68 -prostate specific membrane antigen PET/CT (68Ga-PSMA PET/CT).
Material and Method: A total of 234 consecutive patients with advanced prostate cancer who underwent 68Ga-PSMA PET/CT were included in this retrospective study. Data on previous treatments, Gleason score, serum Prostate Specific Antigen (PSA) levels (ng/mL) and 68Ga-PSMA PET/CT findings were recorded. Results: The mean age of the patients was 67.6 ± 8.5 years. Median PSA level was 21.7 (0.2-880) ng/ml. Pelvic (41%) and abdominal (30.3%) lymph nodes were the most commonly involved lymph nodes, while bone metastases were multimetastatic and bone carcinomatosis in 22.2% and 30.6% of patients, respectively. Other common distant organ metastases were lung (7.6%) and liver (7.2%) metastases. Level 1-4 lymph node positivity was noted in 29.4%, 33.3% and 6.8% of patients with liver metastasis, lung metastasis and seminal vesicle invasion, respectively. Concomitant lung metastasis was evident in 41.1% of patients with liver metastasis, while lung or liver metastasis was evident in 13.6% of patients with seminal vesicle invasion. Bone metastasis was evident in all patients with liver and lung metastasis, and in 65.9% of patients with seminal vesicle invasion. Conclusion:The findings of this study showed the value of 68Ga-PSMA PET/CT in detecting coexistence rate of metastases in advanced prostate cancer. |
[ Turkish ] [ Tam Metin ] [ PDF ] |
[ Ana Sayfa | Editörler | Danışma Kurulu | Dergi Hakkında | İçindekiler | Arşiv | Yayın Arama | Yazarlara Bilgi | E-Posta ] |